| HOME >> MEDICINE >> TECHNOLOGY |
Heightened safety concerns continue to impact pharma
Collaboration between the FDA and EMA is intensifying
EU ban on direct-to-patient communication guidelines partially relaxed
Developed markets exhibit a stable intellectual property environment
It is generally easier to secure patent protection in the US than in the EU
The EU follows the 8+2+1 rule
Japan gives branded pharma companies 8 years of data exclusivity through re-evaluation requirement
Springboarding allows generics manufacturers to access branded drug data in Australia
Loss of Plavix exclusivity in Germany is thought to be an exception
The EU's move to a single patent has been held up
The intellectual property environments in the emerging markets are seen as inadequate
Russia's intellectual properly environment is characterized by corruption
Patent reviews are slow in Brazil
Indian law does not contain statutory data protection
China is not yet affording adequate data protection for new chemical entities
PRICING AND REIMBURSEMENT
Key global pricing and reimbursement controls
Pricing controls
Reimbursement controls
Pricing and reimbursement cuts were key elements included in austerity measures in many developed markets
Patent-protected drugs are spared by Italian price cuts but off-patent and generic drugs suffer
Austerity measures in France impact both prices and reimbursement rates
Spain's price cuts impact both branded and generic medicines
Germany's new law focuses on containing the growth of spending on patent-protected drugs
Australia's changing reimbursement landscape puts pressure on local generics sector
Japan continues to focus on drug price cutting as its main cost-containment measure
US pharma companies are impacted by higher rebates and discount
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |